330 results about "Hepatitis B immunization" patented technology

The invention discloses an application of a POK erythroid myelogenic factor ZBTB7A in resisting hepatitis B virus. Experiments prove that the overexpression of the ZBTB7A can significantly reduce the level of secreted HBV-related virus protein and significantly inhibit HBV transcription and replication, and a new potential target is provided for treatment of hepatitis B. The research prompts that the ZBTB7A can be used as a novel HBV host limiting factor, lays a foundation for developing novel antiviral drugs, provides more effective treatment schemes for clinical treatment, and has wide application prospects and market potential.

The invention provides antisense oligonucleotide for inhibiting expression of hepatitis B virus, and also relates to a pharmaceutical composition of the antisense oligonucleotide. The antisense oligonucleotide or / and the pharmaceutical composition of the antisense oligonucleotide can be used for preparing drugs for treating and / or preventing hepatitis B.

The present invention relates to a viral gene therapy vector for removing hepatitis B viruses, a preparation method therefor, and the use thereof, aiming to solve the problem in which existing viral gene therapy vectors can only inhibit the replication of hepatitis B viruses, but cannot remove virus cccDNA. The vector comprises a promoter, an intron, an enhancer, a nuclear localization signal (NLS) functional domain encoding gene of PGLYRP2 protein, an HBV DNA binding domain encoding gene of the PGLYRP2 protein, a secretory signal peptide functional domain encoding gene of the PGLYRP2 protein, an HBV nucleocapsid-binding functional domain encoding gene of the PGLYRP2 protein, and an IRES fragment. The viral gene therapy vector can remarkably promote the removal of HBVs in the liver of mice and is used for treatment of hepatitis B virus infection.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The present disclosure relates to siRNA for inhibiting hepatitis B virus and uses thereof. In particular to an oligonucleotide for inhibiting HBV or a pharmaceutically acceptable salt thereof, the oligonucleotide comprises an antisense strand, the antisense strand comprises at least one modified nucleotide, and the nucleotide sequence of the antisense strand comprises a sequence or fragment as shown in any one of SEQ ID NO: 3-35. According to the present invention, the siRNA provides significant inhibition effects for HBsAg, HBV DNA and HBeAg generated by cccDNA and host genome integrated HBV DNA in vivo and in vitro, the drug effect is lasting, and compared with the original sequence, the optimized sequence improves the inhibition effect and the drug effect period, and reduces the off-target toxicity;

Use of PGLYRP2 gene and a related drug thereof. The present invention relates to the field of biopharmaceuticals, and in particular, to use of the PGLYRP2 gene and the related drug thereof. The present invention aims to solve the problem that existing drugs can only inhibit the replication of hepatitis B virus and cannot eliminate viral cccDNA. The PGLYRP2 gene is used for preparing a drug for treating a hepatitis B virus infection. The PGLYRP2 gene is used for preparing a drug for eliminating hepatitis B virus cccDNA. Also provided is a gene therapy vector for eliminating hepatitis B virus. The gene therapy vector comprises a promoter, an intron, an enhancer, and a PGLYRP2 gene encoding region. The HBV virus inhibition function and the cccDNA-eliminating effect of the PGLYRP2 protein are defined, so that the elimination of HBV in liver cells and a mouse liver can be significantly promoted.

Provided herein are methods of detecting sources of hepatitis B virus (HBV) surface antigens (HbsAgs) in samples. Some exemplary embodiments include amplifying HBV transcript nucleic acids in or from a sample and quantifying an amount of HBV transcript nucleic acids transcribed from HBV cccDNA and an amount of HBV transcript nucleic acids transcribed from the HBV iDNA. Related systems and other aspects are also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to an mRNA vaccine for preventing or treating hepatitis B virus infection and application of the mRNA vaccine. The mRNA vaccine comprises mRNA for coding hepatitis B virus surface antigen or / and hepatitis B virus core associated antigen or / and hepatitis B virus front surface antigen 1 fusion IgG Fc segment protein, and the mRNA is wrapped by lipid nanoparticles to form a delivery system to be prepared into the mRNA vaccine. The vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen or / and hepatitis B virus core related antigen or / and hepatitis B virus front surface antigen, and can be used for preventing and treating hepatitis B. All the components in the vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and therefore the vaccine preparation has good practical application value.

An oligonucleotide, a conjugate, a composition and the use thereof. The oligonucleotide can inhibit the gene expression of a hepatitis B virus, and can efficiently inhibit the generation of HBsAg and total HBV DNAs, and therefore is expected to realize functional healing of hepatitis B.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:which inhibit the cellular entry of hepatitis B virus (HBV) and / or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and / or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and / or HDV infection. The invention also relates to methods of treating an HBV and / or HDV infection in a subject by administering a therapeutically effective amount of a compound of the present invention.

A method for treating HBV infection in a subject, comprising administering to the subject an anti-pre-S1 antibody or a fragment thereof at a dose of about 0.1 mg / kg to about 80 mg / kg. Also relates to an anti-pre-S1 antibody or a fragment thereof for use in treating HBV infection.

Provided is a chimeric antisense compound comprising a modified oligonucleotide comprising 5′ W1-G1-S1-G2-W2 3′, wherein: W1 is a 5′ wing segment, W2 is a 3′ wing segment, G1 is a first gap segment, S1 is a first separator segment, and G2 is a second gap segment. Also provided is a method for decreasing HBV mRNA, DNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

The invention discloses a detection system for simultaneously detecting HBV (Hepatitis B Virus) DNA (Deoxyribose Nucleic Acid) and HBV RNA (Ribonucleic Acid) based on CRISPR-cas12a / cas13a. According to the invention, a PCR primer is designed to amplify conserved intervals of different genotypes of HBV DNA, and a PCR primer with a T7 promoter is designed to amplify a conserved sequence of HBV RNA. In the same detection system, crRNA of cas12a / cas13a can specifically recognize amplification products of the crRNA respectively, HBV DNA and HBV RNA can be detected in a single tube at the same time, and finally visual detection is achieved through direct color development of dual fluorescence. According to the method, HBV DNA and HBV RNA can be efficiently, specifically and accurately detected, so that the clinical antiviral curative effect of the chronic hepatitis B patient is better monitored, medication is guided, and accurate treatment on the chronic hepatitis B patient is facilitated.

The invention discloses a method for constructing a cancer assessment model, a cancer assessment system, a medium and electronic equipment. According to the evaluation model developed by the invention, the diagnosis efficiency of the hepatitis B virus related liver cancer is remarkably improved, and the evaluation model particularly shows excellent prediction performance in early-stage liver cancer and serum marker negative patients. Compared with a single marker and an existing scoring model, the cancer evaluation model constructed by the method has huge advantages in comprehensive indexes such as AUC, sensitivity and specificity. Although the introduced GP73 is a negative coefficient in the model, the diagnosis performance is effectively improved through the synergistic effect of the GP73 and other markers. The evaluation model constructed by the invention provides a reliable tool for non-invasive prediction and early screening of liver cancer, and has important clinical application value.

The utility model belongs to the technical field of virus detection reagent tube storage equipment, and provides a quantitative reagent kit for hepatitis B virus nucleic acid detection, including a storage box for centrally storing virus reagent tubes, a protection mechanism for improving the protection effect of the device and preventing the reagent tubes from shaking and causing breakage is arranged above the storage box, and a constant temperature mechanism for improving the preservation effect of the reagent tubes is arranged on the outside of the storage box; the utility model can greatly improve the protection safety provided by the virus reagent tubes when they are placed inside the storage box to a certain extent through the protection mechanism, the flip shaft and protection cover plate provided in the protection mechanism not only facilitate the staff to take and put the reagent tubes, but the compression and cooperation of the sliding screw, the clamping plate and the rotator provided in the screw tightening assembly can effectively improve the safety and stability of the reagent tubes placed in the storage box, prevent the reagent tubes from shaking and colliding and causing breakage, and the sponge plate can also prevent damage to the reagent tubes on the basis of improving the compression effect.

The present disclosure relates to methods for generating an immune response for treating or preventing hepatitis B virus infection. The present disclosure also relates to methods for generating MHC-E and / or MHC-II restricted CD8+ T cells for treating or preventing hepatitis B virus infection.

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-4 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-4 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-4 are DFSFSSHA, ISSYDGGTT and AKEGNAFRYFGWLPDYQYFGMDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-4 are QRINSRY, AAS and QQYGNSPLCS in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-4 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.

The application relates to a detection method of anti-preS1 antibody, an anti-preS1 antibody detection kit and application, the application carries out multi-sequence comparison and conservation analysis on preS1 sequences of different genotypes (A, B, C, D and CD mixed type) of HBV, takes type A (AB697487.1), type C (FJ032351.1) and type D (LC519808.1) as reference sequences, based on the sequence consistency standard of 85% of full length and 90% of the key region of functional antibody binding, a highly conservative preS1 full-length antigen sequence is systematically screened out in natural variation, the sequence can cover antigen variation of A-D type HBV, and the sequence is taken as a coating antigen to establish an indirect ELISA detection system, a good linear relationship is presented in the range of 4.88-625 ng / mL, and the Cut-off value is 33.6 ng / mL; clinical verification shows that the method can effectively distinguish chronic hepatitis B patients from healthy control groups, compared with detection methods based on partial fragments or overlapping short fragments, the false negative rate can be significantly reduced, and the method is suitable for HBV infection immune state evaluation, anti-virus curative effect monitoring and prognosis analysis.

A method for detecting hepatitis B virus comprising a step of bringing a sample into contact with an antibody which binds to a surface antigen protein of hepatitis B virus, and a lectin. The surface antigen protein of hepatitis B virus may be an S protein, and the lectin may be wheat germ agglutinin. The detection method may involve an ELISA measurement and may be used for testing, prophylaxis, or planning treatment of hepatitis B virus, and for screening medicines.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

To provide a compound having diacylglycerol kinase α (DGKα) inhibitory activity and useful for treating cancer including solid tumors and viral infections such as HIV or hepatitis B virus infection.SOLUTION: A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided.SELECTED DRAWING: None

The present application discloses the use of TIAR inhibitors for treating hepatitis B virus infection. The present application demonstrates that the host factor TIAR promotes HBV replication by regulating the translation of pgRNA through its binding, i.e. inhibiting the translation of nucleocapsid protein but promoting the translation of Pol. It is also found that TIAR is also packaged into the nucleocapsid of HBV through its binding to pgRNA. The present application provides a new solution for treating HBV infection based on TIAR as a target by reducing the expression of TIAR or inhibiting the binding of TIAR to pgRNA to inhibit HBV replication.

Provided herein are immune-stimulating anti-HBsAg antibody conjugates, such as a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of use thereof for treating, preventing, or alleviating one or more symptoms of HBV infection.

The present disclosure relates to a ribavirin derivative-embedded double-stranded siRNA analogue, a conjugate comprising the same, and salts and uses thereof. The double-stranded siRNA analogue, the conjugate comprising the same, and the salts thereof of the present disclosure can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

Disclosed herein is a novel tool to associate protein cargo molecules to the inside and / or outside of a Hepatitis B Virus (HBV) virus-like particle (VLP). The novel tool being composed of a sulfamoylbenzamide (SBA) antiviral, linker, and protein.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

An antisense oligonucleotide and the use thereof. A series of ASOs are designed on the basis of the genome sequence of a hepatitis B virus (HBV), and are modified by means of using a specific modification mode. Cell and animal experiment results show that some modified ASOs obtained by means of using the specific modification mode can significantly reduce the expression of one or more HBV genes and block the life cycle of viruses, and therefore can be used to develop drugs for treating HBV infection-related diseases.